New York – December 5, 2019 – In separate transactions that closed within a week of each other, Cooley advised on follow-on offerings for Reata Pharmaceuticals and argenx that total more than $1 billion.

Reata closed its $505 million follow-on offering of 2,760,000 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Rich Segal, Div Gupta and Charlie Kim led the team advising the underwriters. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Cantor, Baird and Ladenburg Thalmann acted as co-managers for the offering.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

argenx closed its $557 million follow-on offering of 4,600,000 ordinary shares, which also includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Div Gupta, Rich Segal and Brent Siler led the team advising the underwriters. Morgan Stanley, Cowen, BofA Securities and Evercore acted as joint book-running managers for the offering. Kempen acted as lead manager for the offering and Wolfe Capital Markets and Advisory acted as co-manager.

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.